Appointment
© DEMETA

Nosopharm: Chair with experience

Nosopharm, a company dedicated to the research and development of new anti-infective drugs, has named Jacques Biton as its new chairman of the board, taking over from Gilles Alberici.

Biton is a consultant with Novagreen Conseil, a specialist firm providing scientific and operational support for biotechnology, chemistry and cleantech start-ups. Until 2017, he was CEO at DEMETA, and before that, CEO at Deinove. He holds an engineering degree in industrial biotechnology and an engineering doctorate in microbiology, enzymology and bioconversion from the University of Technology, Compiègne, France. Biton holds more than 25 international patents covering applications in industrial biotechnology and chemistry.